INDV Indivior Pharmaceuticals, Inc.
8-K Current Report
Filed: March 17, 2026
Health Care
Pharmaceutical PreparationsIndivior Pharmaceuticals, Inc. (INDV) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 1.02: Termination of a Material Definitive Agreement
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • Indivior issued convertible notes (144A private placement) to qualified institutional buyers — not publicly offered
- • Max 16,202,200 common shares issuable upon conversion, representing meaningful potential dilution
Item 1.02 · Termination of a Material Definitive Agreement
- • Full prepayment of all outstanding principal, accrued interest, and fees under the Note Purchase Agreement on March 17, 2026
- • Facility originated November 4, 2024, with Piper Sandler Finance LLC as Administrative Agent; terminated same day as prepayment
Other Indivior Pharmaceuticals, Inc. 8-K Filings
Get deeper insights on Indivior Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.